Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast

Carole R. Mendelson, Daniel B. Hardy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

There is convincing evidence to suggest that estrogen and inflammatory mediators play important roles in growth and progression of breast cancer. Moreover, local conversion of androgens to estrogens by aromatase (product of CYP19 gene) occurs in 70% of all breast cancers. The actions of aromatase in both the breast tumor and in surrounding adipose stromal and endothelial cells can result in high local levels of estrogen production that stimulate tumor growth. The efficacy of current endocrine therapies is predicted only if the tumor contains significant amounts of ER. Presence of PR in the tumor also is an important predictor of tumor aggressiveness and responsiveness to endocrine therapy. Immunoreactivity for aromatase in human breast tumors is highly correlated with that for cyclooxygenase 2 (COX-2), the rate-determining enzyme in prostanoid biosynthesis. COX-2 expression also is correlated with expression of HER-2/neu, an oncogene expressed in >30% of breast tumors. In this manuscript, we will review findings to suggest that induction of COX-2 by inflammatory cytokines acting through NF-κB contributes to the increase in CYP19 expression and breast cancer progression, and that PR plays a dominant protective role in breast cancer cells by antagonizing NF-κB activation of COX-2.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume102
Issue number1-5 SPEC. ISS.
DOIs
StatePublished - Dec 2006

Fingerprint

Aromatase
Progesterone Receptors
Tumors
Breast
Breast Neoplasms
Cyclooxygenase 2
Estrogens
Neoplasms
Biosynthesis
Endothelial cells
Stromal Cells
Growth
Oncogenes
Androgens
Prostaglandins
Byproducts
Endothelial Cells
Genes
Chemical activation
Cells

Keywords

  • Aromatase
  • Breast cancer
  • Cyclooxygenase 2
  • Inflammation
  • Nuclear factor κB
  • Progesterone receptor

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast. / Mendelson, Carole R.; Hardy, Daniel B.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 102, No. 1-5 SPEC. ISS., 12.2006, p. 241-249.

Research output: Contribution to journalArticle

@article{8d4c4d9be0e6423abc0621ccbbea840e,
title = "Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast",
abstract = "There is convincing evidence to suggest that estrogen and inflammatory mediators play important roles in growth and progression of breast cancer. Moreover, local conversion of androgens to estrogens by aromatase (product of CYP19 gene) occurs in 70{\%} of all breast cancers. The actions of aromatase in both the breast tumor and in surrounding adipose stromal and endothelial cells can result in high local levels of estrogen production that stimulate tumor growth. The efficacy of current endocrine therapies is predicted only if the tumor contains significant amounts of ER. Presence of PR in the tumor also is an important predictor of tumor aggressiveness and responsiveness to endocrine therapy. Immunoreactivity for aromatase in human breast tumors is highly correlated with that for cyclooxygenase 2 (COX-2), the rate-determining enzyme in prostanoid biosynthesis. COX-2 expression also is correlated with expression of HER-2/neu, an oncogene expressed in >30{\%} of breast tumors. In this manuscript, we will review findings to suggest that induction of COX-2 by inflammatory cytokines acting through NF-κB contributes to the increase in CYP19 expression and breast cancer progression, and that PR plays a dominant protective role in breast cancer cells by antagonizing NF-κB activation of COX-2.",
keywords = "Aromatase, Breast cancer, Cyclooxygenase 2, Inflammation, Nuclear factor κB, Progesterone receptor",
author = "Mendelson, {Carole R.} and Hardy, {Daniel B.}",
year = "2006",
month = "12",
doi = "10.1016/j.jsbmb.2006.09.029",
language = "English (US)",
volume = "102",
pages = "241--249",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-5 SPEC. ISS.",

}

TY - JOUR

T1 - Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast

AU - Mendelson, Carole R.

AU - Hardy, Daniel B.

PY - 2006/12

Y1 - 2006/12

N2 - There is convincing evidence to suggest that estrogen and inflammatory mediators play important roles in growth and progression of breast cancer. Moreover, local conversion of androgens to estrogens by aromatase (product of CYP19 gene) occurs in 70% of all breast cancers. The actions of aromatase in both the breast tumor and in surrounding adipose stromal and endothelial cells can result in high local levels of estrogen production that stimulate tumor growth. The efficacy of current endocrine therapies is predicted only if the tumor contains significant amounts of ER. Presence of PR in the tumor also is an important predictor of tumor aggressiveness and responsiveness to endocrine therapy. Immunoreactivity for aromatase in human breast tumors is highly correlated with that for cyclooxygenase 2 (COX-2), the rate-determining enzyme in prostanoid biosynthesis. COX-2 expression also is correlated with expression of HER-2/neu, an oncogene expressed in >30% of breast tumors. In this manuscript, we will review findings to suggest that induction of COX-2 by inflammatory cytokines acting through NF-κB contributes to the increase in CYP19 expression and breast cancer progression, and that PR plays a dominant protective role in breast cancer cells by antagonizing NF-κB activation of COX-2.

AB - There is convincing evidence to suggest that estrogen and inflammatory mediators play important roles in growth and progression of breast cancer. Moreover, local conversion of androgens to estrogens by aromatase (product of CYP19 gene) occurs in 70% of all breast cancers. The actions of aromatase in both the breast tumor and in surrounding adipose stromal and endothelial cells can result in high local levels of estrogen production that stimulate tumor growth. The efficacy of current endocrine therapies is predicted only if the tumor contains significant amounts of ER. Presence of PR in the tumor also is an important predictor of tumor aggressiveness and responsiveness to endocrine therapy. Immunoreactivity for aromatase in human breast tumors is highly correlated with that for cyclooxygenase 2 (COX-2), the rate-determining enzyme in prostanoid biosynthesis. COX-2 expression also is correlated with expression of HER-2/neu, an oncogene expressed in >30% of breast tumors. In this manuscript, we will review findings to suggest that induction of COX-2 by inflammatory cytokines acting through NF-κB contributes to the increase in CYP19 expression and breast cancer progression, and that PR plays a dominant protective role in breast cancer cells by antagonizing NF-κB activation of COX-2.

KW - Aromatase

KW - Breast cancer

KW - Cyclooxygenase 2

KW - Inflammation

KW - Nuclear factor κB

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=33750970565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750970565&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2006.09.029

DO - 10.1016/j.jsbmb.2006.09.029

M3 - Article

VL - 102

SP - 241

EP - 249

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-5 SPEC. ISS.

ER -